Titan Pharmaceuticals, Inc. (TTNP) EPS Estimated At $-0.18; Shorts at Seaspine Holdings (SPNE) Lowered By 42.53%

March 14, 2018 - By Richard Conner

Analysts expect Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) to report $-0.18 EPS on March, 15.They anticipate $0.03 EPS change or 20.00% from last quarter’s $-0.15 EPS. After having $-0.20 EPS previously, Titan Pharmaceuticals, Inc.’s analysts see -10.00% EPS growth. The stock decreased 3.08% or $0.03 during the last trading session, reaching $0.952. About 71,531 shares traded. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has declined 59.84% since March 14, 2017 and is downtrending. It has underperformed by 76.54% the S&P500.

Seaspine Holdings Corporation (NASDAQ:SPNE) had a decrease of 42.53% in short interest. SPNE’s SI was 20,000 shares in March as released by FINRA. Its down 42.53% from 34,800 shares previously. With 29,100 avg volume, 1 days are for Seaspine Holdings Corporation (NASDAQ:SPNE)’s short sellers to cover SPNE’s short positions. The SI to Seaspine Holdings Corporation’s float is 0.19%. It closed at $10 lastly. It is up 6.47% since March 14, 2017 and is uptrending. It has underperformed by 10.23% the S&P500.

Among 3 analysts covering SeaSpine Hldgs (NASDAQ:SPNE), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SeaSpine Hldgs had 6 analyst reports since June 21, 2017 according to SRatingsIntel. The stock has “Buy” rating by Piper Jaffray on Thursday, September 28. The firm earned “Buy” rating on Tuesday, July 11 by BTIG Research. H.C. Wainwright maintained it with “Buy” rating and $15.0 target in Friday, March 2 report. On Friday, August 18 the stock rating was maintained by Piper Jaffray with “Buy”.

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and Internationally. The company has market cap of $145.38 million. The firm provides orthobiologics and spinal fusion hardware solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. It currently has negative earnings. The Company’s orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company has market cap of $20.19 million. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. It currently has negative earnings. The firm offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: